I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.

Dennis Reilly Biography and Net Worth

CFO of Agile Therapeutics

Reilly has had significant experience with commercial companies in the pharmaceutical and diagnostics sectors. In 2017, he served as Chief Financial and Chief Operating Officer of Invisible Sentinel, Inc., a private company, which BioMerieux acquired in February 2019. From 2009 to 2017, he served as Chief Financial Officer of NeoStrata Company, Inc., a privately held global leader in dermocosmetics, which was sold to Johnson & Johnson Consumer Inc. in 2016. From 2005 to 2008, he served as the Chief Financial Officer, and prior to that as Controller, of Barrier Therapeutics, Inc., a public dermatology focused specialty pharmaceutical company, which was sold to Stiefel Laboratories, Inc. in 2008. Mr. Reilly was the Corporate Controller at the Medicines Company from 2002 to 2005. In addition, held positions of increasing responsibilities at Mobil Oil Corporation, which included financial statement preparation, internal audit, SEC reporting, and financial analysis. Mr. Reilly is a C.P.A., who received his B.S. in Accounting from Villanova and his M.B.A. from Virginia Tech.

What is Dennis Reilly's net worth?: The estimated net worth of Dennis Reilly is at least $341,722.06 as of July 27th, 2021. Mr. Reilly owns 226,306 shares of Agile Therapeutics stock worth more than $341,722 as of December 29th. This net worth estimate does not reflect any other investments that Mr. Reilly may own. Learn More about Dennis Reilly's net worth.
How do I contact Dennis Reilly?: The corporate mailing address for Mr. Reilly and other Agile Therapeutics executives is 101 POOR FARM ROAD, PRINCETON NJ, 08540. Agile Therapeutics can also be reached via phone at (609) 683-1880 and via email at [email protected]. Learn More on Dennis Reilly's contact information.
Has Dennis Reilly been buying or selling shares of Agile Therapeutics?: Dennis Reilly has not been actively trading shares of Agile Therapeutics over the course of the past ninety days. Most recently, on Tuesday, July 27th, Dennis Reilly bought 50,000 shares of Agile Therapeutics stock. The stock was acquired at an average cost of $1.08 per share, with a total value of $54,000.00. Following the completion of the transaction, the chief financial officer now directly owns 226,306 shares of the company's stock, valued at $244,410.48. Learn More on Dennis Reilly's trading history.
Who are Agile Therapeutics' active insiders?: Agile Therapeutics' insider roster includes Alfred Altomari (CEO), Jason Butch (Insider), and Dennis Reilly (CFO). Learn More on Agile Therapeutics' active insiders.

Dennis Reilly Insider Trading History at Agile Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
7/27/2021	Buy	50,000	$1.08	$54,000.00	226,306
5/11/2021	Buy	20,000	$1.35	$27,000.00	176,306
3/23/2021	Buy	50,000	$2.05	$102,500.00	156,306
9/28/2020	Buy	9,000	$2.85	$25,650.00	106,306
3/4/2020	Buy	50,000	$2.32	$116,000.00	59,806

Dennis Reilly Buying and Selling Activity at Agile Therapeutics

Agile Therapeutics Company Overview

Agile Therapeutics, Inc., a women's healthcare company, engages in the research, development, and commercialization of prescription contraceptive products for women in the United States. It offers Twirla, a once-weekly prescription combination hormonal contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other products, including AG200-15 Extended Regimen (ER), a regimen that allows a woman to have four episodes of withdrawal bleeding per year; AG200-15 smaller patch (SmP), which is a regimen designed to provide shorter and lighter withdrawal bleeds, and enhance contraceptive efficacy; AG200-15 ER SmP, a regimen to allow a woman to extend the length of her contraceptive cycle, as well as have shorter and lighter withdrawal bleeding episodes per year; and P-Patch, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen. Agile Therapeutics, Inc. was incorporated in 1997 and is headquartered in Princeton, New Jersey.

Today's Range

Now: $1.51

$1.51

$1.52

50 Day Range

MA: $1.49

$1.43

$1.51

2 Week Range

Now: $1.51

$0.20

$2.63

Volume

120,900 shs

Average Volume

352,864 shs

Market Capitalization

$10.35 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.58

I was wrong. Dead wrong.

From Porter & Company | Ad